Anadys Pharmaceuticals to Present at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference
Posted on: Monday, 26 February 2007, 21:00 CST
SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it will present at the Susquehanna Financial Group's "SIGnificant Investment Options in Healthcare" Conference on Thursday, March 1, 2007 at 3:00 p.m. EST (12:00 p.m. PST). The conference is being held at The Omni Berkshire Place Hotel in New York City.
Lawrence C. Fritz, Ph.D., president and chief executive officer of Anadys Pharmaceuticals, will present an overview of Anadys and its clinical development and discovery programs.
The presentation will be simultaneously webcast and can be accessed on the Company's website at http://www.anadyspharma.com/. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be archived until March 15, 2007.
About Anadys
Anadys Pharmaceuticals, Inc., http://www.anadyspharma.com/, is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company has core expertise in developing Toll-Like Receptor-based small molecule therapeutics and utilizing structure-based drug design coupled with medicinal chemistry to identify new product candidates. Anadys is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2005 and the "Risk Factors" section of Anadys' Form 10-Q for the quarter ended September 30, 2006. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Anadys Pharmaceuticals, Inc.
CONTACT: Vince Reardon, Sr. Director, Investor Relations & CorporateCommunications of Anadys Pharmaceuticals, Inc., +1-858-530-3653,vreardon@anadyspharma.com
Web site: http://www.anadyspharma.com/
Source: PRNewswire-FirstCall
Related Articles
- Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Society's Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
- Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
- Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
- Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
- Jerini Ophthalmic and PR Pharmaceuticals Sign Collaboration Agreement to Develop Sustained-Release Formulations for the Treatment of Eye Diseases
- Historic Addiction Treatment Facility Brighton Hospital Becomes Hythiam's First Combined Inpatient and Outpatient Licensee in Michigan; Hospital Based on 12-Step Philosophy Looks Forward to Enhancing Care With PROMETA(R) Protocols
- Heinz Announces Preliminary Proxy Voting Results; Looks Forward With Confidence to Executing Its Plans to Increase Shareholder Value
- Immunicon Corporation Assay Utilized By Pfizer in Phase I Drug Study; Results Presented at the 2006 ASCO Annual Meeting
- Amylin Pharmaceuticals Provides Update On Clinical Development Programs
- UK Astronomers Look Forward to Looking Back
 |
 |
User Comments (0)
RSS Feeds